Study: NCT02431702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Haloperidol will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Paliperidone ER
Description: Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Paliperidone ER
Description: Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Paliperidone ER
Description: Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Perphenazine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Perphenazine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perphenazine
Description: Perphenazine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be administered in accordance with the label or Investigator's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Risperidone tablets 1-6 mg per day will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Risperidone tablets 1-6 mg per day will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Risperidone tablets 1-6 mg per day will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate Injection (PP1M)
Description: Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate Injection (PP1M)
Description: Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate Injection (PP3M)
Description: Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate Injection (PP3M)
Description: Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate Injection (PP3M)
Description: Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.